Kailera Therapeutics Files Initial Ownership Statement
Ticker: KLRA · Form: 3 · Filed: Apr 16, 2026
Sentiment: neutral
Topics: insider-filing, ownership, sec-form-3
TL;DR
Kailera Therapeutics filed a Form 3 on 4/16/26. Ownership details to follow.
AI Summary
On April 16, 2026, Kailera Therapeutics, Inc. filed an initial statement of beneficial ownership of securities (Form 3). The filing was made by Paula Cloghessy, who is listed as a reporting person with a CIK of 0001744682. The company's mailing address is C/O Translate Bio, Inc., 29 Hartwell Avenue, Lexington MA 02421.
Why It Matters
This filing indicates a new entity or a significant change in ownership structure for Kailera Therapeutics, Inc., which could signal future strategic moves or investments.
Risk Assessment
Risk Level: low — A Form 3 filing is a standard initial disclosure and does not inherently represent a change in the company's financial health or market position.
Key Numbers
- 2026-04-16 — Filing Date (Date of the Form 3 filing)
Key Players & Entities
- Kailera Therapeutics, Inc. (company) — Issuer
- Paula Cloghessy (person) — Reporting Person
- 0001744682 (company) — CIK of Paula Cloghessy
- 0002096997 (company) — CIK of Kailera Therapeutics, Inc.
- 29 Hartwell Avenue, Lexington MA 02421 (location) — Mailing Address for Translate Bio, Inc.
FAQ
What is the purpose of a Form 3 filing?
A Form 3 is an Initial Statement of Beneficial Ownership of Securities, required to be filed by individuals who become a director, officer, or beneficial owner of more than 10% of a class of a company's equity securities.
Who is the reporting person in this filing?
Paula Cloghessy is the reporting person, identified by CIK 0001744682.
What is the CIK for Kailera Therapeutics, Inc.?
The CIK for Kailera Therapeutics, Inc. is 0002096997.
What is the mailing address associated with this filing?
The mailing address is C/O Translate Bio, Inc., 29 Hartwell Avenue, Lexington MA 02421.
When was this filing accepted by the SEC?
The filing was accepted on 2026-04-16 at 19:35:26.
Filing Details
This Initial Statement of Beneficial Ownership (Form 3) was filed with the SEC on April 16, 2026 by Paula Cloghessy regarding Kailera Therapeutics, Inc. (KLRA). Form 3 filings establish the initial ownership position of company insiders when they first assume their role.